Multiorgan Metabolic Imaging Response Assessment of Abemaciclib

Conditions:   Esophageal Adenocarcinoma;   Esophagus SCC;   Cholangiocarcinoma;   Urothelial/Bladder Cancer, Nos;   Endometrial Cancer
Intervention:   Drug: Abemaciclib
Sponsors:   Jules Bordet Institute;   Eli Lilly and Company
Not yet recruiting

http://ift.tt/2hqarfs